February 03, 2020   Prosthesis system may help blind patients 'see' again Learn how the visual cortical prosthesis system provided some functional vision to blind patients in a 12-month assessment of the device. Find out   Brolucizumab in the real world: What it means for physicians, patients Retinal specialists are ushering in a new year with the availability of a new anti–vascular endothelial growth factor (VEGF) therapy since the recent FDA approval of brolucizumab for the treatment of patients with wet age-related macular degeneration (AMD). Learn more   Coming to terms with ‘ultra-widefield’ and ‘widefield’ imaging The International Widefield Imaging Study Group (IWISG)—a physician panel with expertise in retinal imaging—has released recommendations for classifications and guidelines for defining “widefield” and “ultra-widefield” imaging. Read more   RELATED ARTICLES What deep learning means for future of diabetic retinopathy screening Study targets subretinal option for AMD treatment Tracking anti-VEGF use among Medicare Part B beneficiaries